In This Article:
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History
MIAMI, April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").
Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.
In DOMA Perpetual's view, the announced initiatives reflect Pacira's robust financial position and the Board's commitment to disciplined capital allocation. The combination of the $300 million dollar share repurchase program and a new emphasis on increasing margins at the pre-tax net income level is anticipated to strengthen shareholder returnii. The onus now falls on management to effectively execute these important initiatives.
"After engaging in conversations with representatives of the Company's Board and management team, we are encouraged by the clear steps Pacira is taking to drive long-term value creation," said Pedro Escudero, CEO and CIO of DOMA Perpetual. "We believe Pacira has entered a period of rapid growth; the new capital allocation priorities reflect the Company's considerable momentum as it continues scaling earnings and free cash flow, enabling it to return meaningful capital to shareholders while still investing in growth. It is our conviction the stock is undervalued relative to its historical average valuation and, more importantly, relative to the multiyear cycle of growth ahead."
Contact:
DOMA Perpetual Capital Management LLC
ir@domaperpetual.com
Disclaimer
This press release has been prepared by DOMA Perpetual Management LLC and its affiliates ("DOMA Perpetual"). The views expressed herein reflect the opinions of DOMA Perpetual and are based on publicly available information with respect to Pacira BioSciences, Inc. ("Pacira" or the "Company"). DOMA Perpetual recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with DOMA Perpetual's conclusions. DOMA Perpetual reserves the right to change or modify any of such views or opinions at any time and for any reason and expressly disclaims any obligation to correct, update, or revise the information contained herein or to otherwise provide any additional materials.